{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:42:05Z","timestamp":1790743325939,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.contraception.2012.01.010","type":"journal-article","created":{"date-parts":[[2012,3,23]],"date-time":"2012-03-23T12:17:02Z","timestamp":1332505022000},"page":"337-344","source":"Crossref","is-referenced-by-count":27,"title":["Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women"],"prefix":"10.1016","volume":"86","author":[{"given":"Hartmut","family":"Blode","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Zeun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Parke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Mellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2012.01.010_bb0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejogrb.2009.11.001","article-title":"Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate\/dienogest): a phase III trial","volume":"149","author":"Palacios","year":"2010","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.contraception.2012.01.010_bb0010","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.contraception.2009.03.018","article-title":"Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate\/dienogest and ethinyl estradiol\/levonorgestrel","volume":"80","author":"Ahrendt","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2012.01.010_bb0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/13625180902850039","article-title":"Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest","volume":"14","author":"Zeun","year":"2009","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2012.01.010_bb0020","series-title":"Handbook of experimental pharmacology","first-page":"261","article-title":"Pharmacokinetics of exogenous natural and synthetic estrogens and antiestrogens","author":"Kuhnz","year":"1999"},{"key":"10.1016\/j.contraception.2012.01.010_bb0025","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1021\/tx970217f","article-title":"Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes","volume":"11","author":"Yamazaki","year":"1998","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.contraception.2012.01.010_bb0030","author":"Bayer HealthCare Pharmaceuticals"},{"key":"10.1016\/j.contraception.2012.01.010_bb0035","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","article-title":"The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective","volume":"31","author":"Bjornsson","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.contraception.2012.01.010_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","article-title":"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition","volume":"38","author":"Dresser","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.contraception.2012.01.010_bb0045","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/0091270007312153","article-title":"New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process","volume":"48","author":"Huang","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2012.01.010_bb0050","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1080\/03602530701690374","article-title":"Drugs as CYP3A probes, inducers, and inhibitors","volume":"39","author":"Liu","year":"2007","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.contraception.2012.01.010_bb0055","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0009-9236(99)70138-4","article-title":"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive","volume":"65","author":"Barditch-Crovo","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.contraception.2012.01.010_bb0060","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0029-7844(01)01532-0","article-title":"Drug interactions between oral contraceptives and antibiotics","volume":"98","author":"Dickinson","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2012.01.010_bb0065","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/009127009803801109","article-title":"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone","volume":"38","author":"LeBel","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2012.01.010_bb0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0010-7824(99)00009-8","article-title":"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. A literature review","volume":"59","author":"Weaver","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2012.01.010_bb0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00003088-199936050-00001","article-title":"Interactions between oral contraceptives and antifungals\/antibacterials. Is contraceptive failure the result?","volume":"36","author":"Weisberg","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.contraception.2012.01.010_bb0080","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00003088-200746020-00003","article-title":"Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug","volume":"46","author":"Zhang","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.contraception.2012.01.010_bb0085","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/BF01733779","article-title":"Pharmacokinetics of oral and intravenous rifampicin during chronic administration","volume":"63","author":"Loos","year":"1985","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.contraception.2012.01.010_bb0090","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","article-title":"Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring","volume":"29","author":"Zhou","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.contraception.2012.01.010_bb0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/09513590500431482","article-title":"High-dose pilot study with the novel progestogen dienogestin patients with endometriosis","volume":"22","author":"Schindler","year":"2006","journal-title":"Gynecol Endocrinol"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782412000418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782412000418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,25]],"date-time":"2018-11-25T00:58:20Z","timestamp":1543107500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782412000418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0010782412000418"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2012.01.010","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}